Ethyl pyruvate enhances spontaneous remyelination by targeting microglia phagocytosis.
Animals
Behavior, Animal
/ drug effects
Cell Line
Cell Movement
/ drug effects
Cell Survival
/ drug effects
Cuprizone
Cytokines
/ immunology
Demyelinating Diseases
/ chemically induced
Disease Models, Animal
Male
Mice, Inbred C57BL
Microglia
/ drug effects
Multiple Sclerosis
/ drug therapy
Phagocytosis
/ drug effects
Pyruvates
/ pharmacology
Remyelination
/ drug effects
Cuprizone-induced demyelination
Ethyl pyruvate
Microglia
Phagocytosis
Remyelination
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
22
05
2019
revised:
03
09
2019
accepted:
21
09
2019
pubmed:
5
11
2019
medline:
25
4
2020
entrez:
3
11
2019
Statut:
ppublish
Résumé
Ethyl pyruvate (EP), a simple derivative of the endogenous energy substrate pyruvate, provides strong anti-inflammatory and anti-oxidative properties. but its role in remyelination has not been explored. In this study, EP efficiently improved the behavioural performance and histological demyelination in cuprizone (CPZ)-induced mouse model. In terms of action, EP treatment enhanced microglia migration, increased the phagocytosis of myelin debris by BV2 microglia and primary microglia, induced cell proliferation and subsequent cell death. At the same time, EP induced microglia to exhibit M2 phenotype, representing decreased iNOS/TNF-α and increased Arg-1/IL-10. In addition, EP decreased microglia enrichment in myelin sheath, and declined TLR4/p-NF-kb/p65 and IL-1β and IL-6, inhibiting microglia-mediated neuroinflammation. As a result, EP treatment promoted the generation of oligodendrocyte progenitor cells (OPCs) and the differentiation from maturation to mature oligodendrocytes, which may be related to the up-regulation of Sox2. Given these data, we provided the proof-of-experiment that EP should be beneficial in multiple sclerosis or demyelinating lesions. However, further studies on the possibility to use EP as therapeutic application are warranted.
Identifiants
pubmed: 31677497
pii: S1567-5769(19)31105-1
doi: 10.1016/j.intimp.2019.105929
pii:
doi:
Substances chimiques
Cytokines
0
Pyruvates
0
ethyl pyruvate
03O98E01OB
Cuprizone
5N16U7E0AO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105929Informations de copyright
Copyright © 2019. Published by Elsevier B.V.